The FDA will speed up its review of Tagrisso plus chemotherapy for patients with advanced or metastatic EGFR-mutant non-small cell lung cancer after the regimen led to improved outcomes in a phase 3 ...

AstraZeneca Plc's AZN supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the U.S. for locally advanced or ...

Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival ...

SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity Susan Galbraith, ...

AstraZeneca AZN announced that the FDA has accepted its supplemental new drug application (sNDA), seeking expanded use of its blockbuster lung cancer drug, Tagrisso (osimertinib) in EGFR-mutated lung ...

The U.S. Food and Drug Administration (FDA) granted priority review to AstraZeneca's (NASDAQ:AZN) application seeking expanded approval of Tagrisso to treat certain patients with a type of non-small ...

Tagrisso combined with chemotherapy improved overall survival in EGFR-mutated NSCLC patients, including those with poor prognostic factors, compared to Tagrisso alone. The FLAURA2 trial demonstrated ...

Oct 16 (Reuters) - A combination of AstraZeneca's (AZN.L), opens new tab blockbuster cancer drug Tagrisso, with chemotherapy to treat a type of lung cancer, has been accepted and granted priority ...

How Well Does Tagrisso Work for Lung Cancer? The FDA approved Tagrisso based on clinical trials for EGFR-mutated lung cancer in several different scenarios. Tagrisso was studied in people who had lung ...

Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...